1	Vascular	Vascular	B-NP	JJ	O	2	NMOD	-1
2	proliferation	proliferation	I-NP	NN	O	5	NMOD	2	proliferation
3	and	and	O	CC	O	5	NMOD	-1
4	enhanced	enhance	B-VP	VBN	O	5	NMOD	17	enhanced
5	expression	expression	B-NP	NN	O	0	ROOT	9	expression
6	of	of	B-PP	IN	O	5	NMOD	-1
7	endothelial	endothelial	B-NP	JJ	B-protein	10	NMOD	-1
8	nitric	nitric	I-NP	JJ	I-protein	10	NMOD	-1
9	oxide	oxide	I-NP	NN	I-protein	10	NMOD	-1
10	synthase	synthase	I-NP	NN	I-protein	6	PMOD	-1
11	in	in	B-PP	IN	O	5	NMOD	-1
12	human	human	B-NP	JJ	O	13	NMOD	-1
13	peritoneum	peritoneum	I-NP	NN	O	11	PMOD	-1
14	exposed	expose	B-VP	VBN	O	13	NMOD	0
15	to	to	B-PP	TO	O	14	VMOD	-1
16	long-term	long-term	B-NP	JJ	O	18	NMOD	-1
17	peritoneal	peritoneal	I-NP	JJ	O	18	NMOD	-1
18	dialysis	dialysis	I-NP	NN	O	15	PMOD	-1
19	.	.	O	.	O	5	P	-1

1	Long-term	Long-term	B-NP	JJ	O	3	NMOD	-1
2	peritoneal	peritoneal	I-NP	JJ	O	3	NMOD	-1
3	dialysis	dialysis	I-NP	NN	O	7	SUB	-1
4	(	(	O	(	O	6	DEP	-1
5	PD	PD	B-NP	NN	O	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	is	be	B-VP	VBZ	O	0	ROOT	-1
8	associated	associate	I-VP	VBN	O	7	VC	0
9	with	with	B-PP	IN	O	8	VMOD	-1
10	alterations	alteration	B-NP	NNS	O	9	PMOD	0
11	in	in	B-PP	IN	O	10	NMOD	-1
12	peritoneal	peritoneal	B-NP	JJ	O	13	NMOD	-1
13	permeability	permeability	I-NP	NN	O	15	NMOD	-1
14	and	and	I-NP	CC	O	15	NMOD	-1
15	loss	loss	I-NP	NN	O	11	PMOD	0
16	of	of	B-PP	IN	O	15	NMOD	-1
17	ultrafiltration	ultrafiltration	B-NP	NN	O	16	PMOD	-1
18	.	.	O	.	O	7	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	changes	change	I-NP	NNS	O	3	SUB	0
3	originate	originate	B-VP	VBP	O	17	VMOD	0
4	from	from	B-PP	IN	O	3	VMOD	-1
5	increased	increase	B-NP	VBN	O	8	NMOD	17	increased
6	peritoneal	peritoneal	I-NP	JJ	O	8	NMOD	-1
7	surface	surface	I-NP	NN	O	8	NMOD	-1
8	area	area	I-NP	NN	O	4	PMOD	-1
9	,	,	O	,	O	17	P	-1
10	but	but	O	CC	O	17	VMOD	-1
11	the	the	B-NP	DT	O	15	NMOD	-1
12	morphologic	morphologic	I-NP	JJ	O	15	NMOD	-1
13	and	and	I-NP	CC	O	15	NMOD	-1
14	molecular	molecular	I-NP	JJ	O	15	NMOD	-1
15	mechanisms	mechanism	I-NP	NNS	O	17	SUB	-1
16	involved	involve	B-VP	VBN	O	15	NMOD	0
17	remain	remain	B-VP	VBP	O	0	ROOT	-1
18	unknown	unknown	B-ADJP	JJ	O	17	PRD	-1
19	.	.	O	.	O	17	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	hypothesis	hypothesis	I-NP	NN	O	33	SUB	-1
3	that	that	B-SBAR	IN	O	2	NMOD	-1
4	modifications	modification	B-NP	NNS	O	17	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	activity	activity	B-NP	NN	O	8	NMOD	0
7	and/or	and/or	O	CC	O	8	NMOD	-1
8	expression	expression	B-NP	NN	O	5	PMOD	9	expression
9	of	of	B-PP	IN	O	8	NMOD	-1
10	nitric	nitric	B-NP	JJ	B-protein	16	NMOD	-1
11	oxide	oxide	I-NP	NN	I-protein	16	NMOD	-1
12	synthase	synthase	I-NP	NN	I-protein	16	NMOD	-1
13	(	(	O	(	I-protein	16	NMOD	-1
14	NOS	NOS	B-NP	NN	I-protein	16	NMOD	-1
15	)	)	O	)	I-protein	16	NMOD	-1
16	isozymes	isozyme	B-NP	NNS	I-protein	9	PMOD	-1
17	might	might	B-VP	MD	O	3	SBAR	-1
18	play	play	I-VP	VB	O	17	VC	0
19	a	a	B-NP	DT	O	20	NMOD	-1
20	role	role	I-NP	NN	O	18	OBJ	0
21	in	in	B-PP	IN	O	18	VMOD	-1
22	these	these	B-NP	DT	O	23	NMOD	-1
23	modifications	modification	I-NP	NNS	O	21	PMOD	-1
24	,	,	O	,	O	18	P	-1
25	via	via	B-PP	IN	O	18	VMOD	0
26	enhanced	enhance	B-NP	VBN	O	28	NMOD	17	enhanced
27	local	local	I-NP	JJ	O	28	NMOD	-1
28	production	production	I-NP	NN	O	25	PMOD	8	production
29	of	of	B-PP	IN	O	28	NMOD	-1
30	nitric	nitric	B-NP	JJ	O	31	NMOD	-1
31	oxide	oxide	I-NP	NN	O	29	PMOD	-1
32	,	,	O	,	O	2	P	-1
33	was	be	B-VP	VBD	O	0	ROOT	-1
34	tested	test	I-VP	VBN	O	33	VC	-1
35	in	in	B-PP	IN	O	34	VMOD	-1
36	this	this	B-NP	DT	O	37	NMOD	-1
37	study	study	I-NP	NN	O	35	PMOD	-1
38	.	.	O	.	O	33	P	-1

1	NOS	NOS	B-NP	NN	O	2	NMOD	-1
2	activities	activity	I-NP	NNS	O	3	SUB	0
3	were	be	B-VP	VBD	O	0	ROOT	-1
4	measured	measure	I-VP	VBN	O	3	VC	-1
5	by	by	B-PP	IN	O	4	VMOD	-1
6	the	the	B-NP	DT	O	8	NMOD	-1
7	L-citrulline	L-citrulline	I-NP	NN	O	8	NMOD	-1
8	assay	assay	I-NP	NN	O	5	PMOD	-1
9	in	in	B-PP	IN	O	4	VMOD	-1
10	peritoneal	peritoneal	B-NP	JJ	O	11	NMOD	-1
11	biopsies	biopsy	I-NP	NNS	O	9	PMOD	-1
12	from	from	B-PP	IN	O	11	NMOD	-1
13	seven	seven	B-NP	CD	O	15	NMOD	-1
14	control	control	I-NP	NN	O	15	NMOD	0
15	subjects	subject	I-NP	NNS	O	12	PMOD	-1
16	,	,	O	,	O	3	P	-1
17	eight	eight	B-NP	CD	O	19	NMOD	-1
18	uremic	uremic	I-NP	JJ	O	19	NMOD	-1
19	patients	patient	I-NP	NNS	O	30	NMOD	-1
20	immediately	immediately	B-ADVP	RB	O	19	NMOD	-1
21	before	before	B-PP	IN	O	20	DEP	-1
22	the	the	B-NP	DT	O	23	NMOD	-1
23	onset	onset	I-NP	NN	O	21	PMOD	-1
24	of	of	B-PP	IN	O	23	NMOD	-1
25	PD	PD	B-NP	NN	O	24	PMOD	-1
26	,	,	O	,	O	30	P	-1
27	and	and	O	CC	O	30	NMOD	-1
28	13	13	B-NP	CD	O	30	NMOD	-1
29	uremic	uremic	I-NP	JJ	O	30	NMOD	-1
30	patients	patient	I-NP	NNS	O	3	VMOD	-1
31	on	on	B-PP	IN	O	30	NMOD	-1
32	short-term	short-term	O	JJ	O	55	NMOD	-1
33	(	(	O	(	O	42	DEP	-1
34	less	less	B-NP	JJR	O	35	AMOD	-1
35	than	than	I-NP	IN	O	37	NMOD	-1
36	18	18	I-NP	CD	O	35	AMOD	-1
37	mo	mo	I-NP	NN	O	42	DEP	-1
38	,	,	O	,	O	42	P	-1
39	n	n	B-NP	NN	O	41	SUB	-1
40	=	=	B-VP	JJ	O	41	VMOD	-1
41	6	6	B-NP	CD	O	42	DEP	-1
42	)	)	O	)	O	32	AMOD	-1
43	or	or	O	CC	O	55	NMOD	-1
44	long-term	long-term	B-ADJP	JJ	O	55	NMOD	-1
45	(	(	O	(	O	55	NMOD	-1
46	greater	great	B-NP	JJR	O	47	AMOD	-1
47	than	than	I-NP	IN	O	49	NMOD	-1
48	18	18	I-NP	CD	O	47	AMOD	-1
49	mo	mo	I-NP	NN	O	55	NMOD	-1
50	,	,	O	,	O	55	P	-1
51	n	n	B-NP	NN	O	53	SUB	-1
52	=	=	B-VP	SYM	O	53	VMOD	-1
53	7	7	B-NP	CD	O	55	NMOD	-1
54	)	)	O	)	O	53	DEP	-1
55	PD	PD	B-NP	NN	O	31	PMOD	-1
56	.	.	O	.	O	3	P	-1

1	Peritoneal	Peritoneal	B-NP	JJ	B-protein	3	NMOD	-1
2	NOS	NOS	I-NP	NN	I-protein	3	NMOD	-1
3	activity	activity	I-NP	NN	O	4	SUB	0
4	is	be	B-VP	VBZ	O	0	ROOT	-1
5	increased	increase	I-VP	VBN	O	4	VC	17	increased
6	fivefold	fivefold	B-ADVP	RB	O	5	VMOD	-1
7	in	in	B-PP	IN	O	5	VMOD	-1
8	long-term	long-term	B-NP	JJ	O	10	NMOD	-1
9	PD	PD	I-NP	NN	O	10	NMOD	-1
10	patients	patient	I-NP	NNS	O	7	PMOD	-1
11	compared	compare	B-PP	VBN	O	5	VMOD	-1
12	with	with	B-PP	IN	O	11	PMOD	-1
13	control	control	B-NP	NN	O	14	NMOD	0
14	subjects	subject	I-NP	NNS	O	12	PMOD	-1
15	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	7	VMOD	-1
2	uremic	uremic	B-NP	JJ	O	3	NMOD	-1
3	patients	patient	I-NP	NNS	O	1	PMOD	-1
4	,	,	O	,	O	7	P	-1
5	NOS	NOS	B-NP	NN	B-protein	6	NMOD	-1
6	activity	activity	I-NP	NN	O	7	SUB	0
7	is	be	B-VP	VBZ	O	0	ROOT	-1
8	positively	positively	I-VP	RB	O	7	VMOD	-1
9	correlated	correlate	I-VP	VBN	O	7	VC	-1
10	with	with	B-PP	IN	O	9	VMOD	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	duration	duration	I-NP	NN	O	10	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	PD	PD	B-NP	NN	O	13	PMOD	-1
15	.	.	O	.	O	7	P	-1

1	Increased	Increase	B-NP	VBN	O	3	NMOD	17	Increased
2	NOS	NOS	I-NP	NN	B-protein	3	NMOD	-1
3	activity	activity	I-NP	NN	O	4	SUB	0
4	is	be	B-VP	VBZ	O	0	ROOT	-1
5	mediated	mediate	I-VP	VBN	O	4	VC	16	mediated
6	solely	solely	B-ADVP	RB	O	7	PMOD	-1
7	by	by	B-PP	IN	O	5	VMOD	-1
8	Ca	Ca	B-NP	NN	B-protein	13	NMOD	-1
9	(	(	O	(	I-protein	13	NMOD	-1
10	2+	2+	B-ADJP	JJ	I-protein	13	NMOD	-1
11	)	)	O	)	I-protein	13	NMOD	-1
12	-dependent	-dependent	B-NP	JJ	I-protein	13	NMOD	-1
13	NOS	NOS	I-NP	NN	I-protein	7	PMOD	-1
14	and	and	O	CC	O	4	VMOD	-1
15	,	,	O	,	O	4	P	-1
16	as	as	B-SBAR	IN	O	4	VMOD	-1
17	shown	show	B-VP	VBN	O	16	SBAR	-1
18	by	by	B-PP	IN	O	17	VMOD	-1
19	immunoblotting	immunoblotting	B-NP	NN	O	22	NMOD	-1
20	,	,	O	,	O	22	P	-1
21	an	an	B-NP	DT	O	22	NMOD	-1
22	upregulation	upregulation	I-NP	NN	O	18	PMOD	17	upregulation
23	of	of	B-PP	IN	O	22	NMOD	-1
24	endothelial	endothelial	B-NP	JJ	B-protein	25	NMOD	-1
25	NOS	NOS	I-NP	NN	I-protein	23	PMOD	-1
26	.	.	O	.	O	4	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	biologic	biologic	I-NP	JJ	O	3	NMOD	-1
3	relevance	relevance	I-NP	NN	O	10	SUB	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	increased	increase	B-NP	VBN	O	6	NMOD	17	increased
6	NOS	NOS	I-NP	NN	B-protein	4	PMOD	-1
7	in	in	B-PP	IN	O	3	NMOD	-1
8	long-term	long-term	B-NP	JJ	O	9	NMOD	-1
9	PD	PD	I-NP	NN	O	7	PMOD	-1
10	was	be	B-VP	VBD	O	0	ROOT	-1
11	demonstrated	demonstrate	I-VP	VBN	O	10	VC	-1
12	by	by	B-PP	IN	O	11	VMOD	-1
13	enhanced	enhance	B-NP	VBN	O	15	NMOD	17	enhanced
14	nitrotyrosine	nitrotyrosine	I-NP	NN	O	15	NMOD	-1
15	immunoreactivity	immunoreactivity	I-NP	NN	O	19	NMOD	-1
16	and	and	O	CC	O	19	NMOD	-1
17	a	a	B-NP	DT	O	19	NMOD	-1
18	significant	significant	I-NP	JJ	O	19	NMOD	-1
19	increase	increase	I-NP	NN	O	25	NMOD	17	increase
20	in	in	B-PP	IN	O	19	NMOD	-1
21	vascular	vascular	B-NP	JJ	O	22	NMOD	-1
22	density	density	I-NP	NN	O	20	PMOD	-1
23	and	and	O	CC	O	25	NMOD	-1
24	endothelial	endothelial	B-NP	JJ	O	25	NMOD	-1
25	area	area	I-NP	NN	O	12	PMOD	-1
26	in	in	B-PP	IN	O	25	NMOD	-1
27	the	the	B-NP	DT	O	28	NMOD	-1
28	peritoneum	peritoneum	I-NP	NN	O	26	PMOD	-1
29	.	.	O	.	O	10	P	-1

1	Immunoblotting	Immunoblotting	B-NP	NN	O	4	NMOD	-1
2	and	and	I-NP	CC	O	4	NMOD	-1
3	immunostaining	immunostaining	I-NP	NN	O	4	NMOD	-1
4	studies	study	I-NP	NNS	O	5	SUB	-1
5	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT	-1
6	an	an	B-NP	DT	O	7	NMOD	-1
7	upregulation	upregulation	I-NP	NN	O	5	OBJ	17	upregulation
8	of	of	B-PP	IN	O	7	NMOD	-1
9	vascular	vascular	B-NP	JJ	B-protein	12	NMOD	-1
10	endothelial	endothelial	I-NP	JJ	I-protein	12	NMOD	-1
11	growth	growth	I-NP	NN	I-protein	12	NMOD	0
12	factor	factor	I-NP	NN	I-protein	8	PMOD	-1
13	(	(	O	(	O	15	DEP	-1
14	VEGF	VEGF	B-NP	NN	B-protein	15	DEP	-1
15	)	)	O	)	O	12	NMOD	-1
16	mostly	mostly	B-PP	RB	O	17	PMOD	-1
17	along	along	I-PP	IN	O	12	NMOD	-1
18	the	the	B-NP	DT	O	19	NMOD	-1
19	endothelium	endothelium	I-NP	NN	O	17	PMOD	-1
20	lining	line	B-VP	VBG	O	19	NMOD	-1
21	peritoneal	peritoneal	B-NP	JJ	O	23	NMOD	-1
22	blood	blood	I-NP	NN	O	23	NMOD	-1
23	vessels	vessel	I-NP	NNS	O	20	OBJ	-1
24	in	in	B-PP	IN	O	20	VMOD	-1
25	long-term	long-term	B-NP	JJ	O	27	NMOD	-1
26	PD	PD	I-NP	NN	O	27	NMOD	-1
27	patients	patient	I-NP	NNS	O	24	PMOD	-1
28	.	.	O	.	O	5	P	-1

1	In	In	B-PP	IN	O	6	VMOD	-1
2	the	the	B-NP	DT	O	3	NMOD	-1
3	latter	latter	I-NP	JJ	O	1	PMOD	-1
4	,	,	I-NP	,	O	6	P	-1
5	VEGF	VEGF	I-NP	NN	B-protein	6	SUB	-1
6	colocalized	colocalize	B-VP	VBD	O	0	ROOT	14	colocalized
7	with	with	B-PP	IN	O	6	VMOD	-1
8	the	the	B-NP	DT	O	14	NMOD	-1
9	advanced	advance	I-NP	VBN	O	14	NMOD	-1
10	glycation	glycation	I-NP	NN	O	14	NMOD	-1
11	end	end	I-NP	NN	O	14	NMOD	-1
12	product	product	I-NP	NN	O	14	NMOD	-1
13	pentosidine	pentosidine	I-NP	NN	O	14	NMOD	-1
14	deposits	deposit	I-NP	NNS	O	7	PMOD	-1
15	.	.	O	.	O	6	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	data	datum	I-NP	NNS	O	3	SUB	-1
3	provide	provide	B-VP	VBP	O	0	ROOT	-1
4	a	a	B-NP	DT	O	14	NMOD	-1
5	morphologic	morphologic	I-NP	JJ	O	14	NMOD	-1
6	(	(	O	(	O	12	DEP	-1
7	angiogenesis	angiogenesis	B-NP	NN	O	11	NMOD	3	angiogenesis
8	and	and	O	CC	O	11	NMOD	-1
9	increased	increase	B-VP	VBD	O	11	NMOD	17	increased
10	endothelial	endothelial	B-NP	JJ	O	11	NMOD	-1
11	area	area	I-NP	NN	O	12	DEP	-1
12	)	)	O	)	O	5	AMOD	-1
13	and	and	O	CC	O	14	NMOD	-1
14	molecular	molecular	B-ADJP	JJ	O	3	VMOD	-1
15	(	(	O	(	O	23	DEP	-1
16	enhanced	enhance	B-NP	VBN	O	18	NMOD	17	enhanced
17	NOS	NOS	I-NP	NN	B-protein	18	NMOD	-1
18	activity	activity	I-NP	NN	O	22	NMOD	0
19	and	and	O	CC	O	22	NMOD	-1
20	endothelial	endothelial	B-NP	JJ	B-protein	21	NMOD	-1
21	NOS	NOS	I-NP	NN	I-protein	22	NMOD	-1
22	upregulation	upregulation	I-NP	NN	O	23	DEP	17	upregulation
23	)	)	O	)	O	14	NMOD	-1
24	basis	basis	B-NP	NN	O	14	PMOD	-1
25	for	for	B-PP	IN	O	14	AMOD	-1
26	explaining	explain	B-VP	VBG	O	25	PMOD	-1
27	the	the	B-NP	DT	O	29	NMOD	-1
28	permeability	permeability	I-NP	NN	O	29	NMOD	-1
29	changes	change	I-NP	NNS	O	26	OBJ	0
30	observed	observe	B-VP	VBN	O	29	NMOD	0
31	in	in	B-PP	IN	O	30	VMOD	-1
32	long-term	long-term	B-NP	JJ	O	33	NMOD	-1
33	PD	PD	I-NP	NN	O	31	PMOD	-1
34	.	.	O	.	O	3	P	-1

1	They	They	B-NP	PRP	O	3	SUB	-1
2	also	also	B-ADVP	RB	O	3	VMOD	-1
3	support	support	B-VP	VBP	O	0	ROOT	0
4	the	the	B-NP	DT	O	5	NMOD	-1
5	implication	implication	I-NP	NN	O	14	NMOD	0
6	of	of	B-PP	IN	O	5	NMOD	-1
7	local	local	B-NP	JJ	O	12	NMOD	-1
8	advanced	advance	I-NP	VBN	O	12	NMOD	-1
9	glycation	glycation	I-NP	NN	O	12	NMOD	-1
10	end	end	I-NP	NN	O	12	NMOD	-1
11	product	product	I-NP	NN	O	12	NMOD	-1
12	deposits	deposit	I-NP	NNS	O	6	PMOD	-1
13	and	and	O	CC	O	14	NMOD	-1
14	liberation	liberation	B-NP	NN	O	3	OBJ	14	liberation
15	of	of	B-PP	IN	O	14	NMOD	-1
16	VEGF	VEGF	B-NP	NN	B-protein	15	PMOD	-1
17	in	in	B-PP	IN	O	14	NMOD	-1
18	that	that	B-NP	DT	O	19	NMOD	-1
19	process	process	I-NP	NN	O	17	PMOD	-1
20	.	.	O	.	O	3	P	-1

